Key result
Prompt influenza antivirals in RA linked to ~21% fewer outpatient visits over 14 days.
Why the study?
Patients with rheumatoid arthritis are vulnerable to severe influenza complications, but differences in health care resource use and costs with antiviral treatment were unclear.
Does prompt antiviral treatment reduce health care resource use and costs in US patients with rheumatoid arthritis and influenza?
Cohort (n=3,957)
Does prompt antiviral treatment reduce health care resource use and costs in US patients with rheumatoid arthritis and influenza?
Absolute Event Rate: 0.96% vs 1.21%
p-value: p=<0.001
Prompt antiviral treatment after influenza diagnosis in patients with rheumatoid arthritis may reduce healthcare resource use and costs.
May reduce ED visits and costs with antivirals in RA-influenza; hypothesis-generating, needs RCTs before practice change.
Objective Patients with rheumatoid arthritis (RA) are vulnerable to severe complications of influenza. We assessed whether health care resource use (HRU) and costs differed between patients with RA and influenza who received antiviral medication compared with matched patients with RA and influenza not receiving antiviral therapy. Methods This was a retrospective US health insurance claims analysis over three influenza seasons (each October to April) in 2016‐2019. Adults with RA and a subsequent diagnosis of influenza were included. Treated patients (receiving antiviral influenza treatment within 2 days of diagnosis) and untreated patients were propensity score matched using baseline covariates. HRU and costs were assessed for inpatient, emergency department (ED), and outpatient visits and compared between cohorts using χ2 tests and t tests. Results After matching, 2638 treated and 1319 untreated patients were included. For treated versus untreated patients, the mean number of all‐cause outpatient visits was 0.96 versus 1.21 during 14 days of follow‐up (P < 0.001) and 1.94 versus 2.24 over 28 days (P = 0.001), respectively. Over 28 days, the mean number of all‐cause ED visits was lower among treated (0.23) than untreated (0.30) patients (P = 0.042). The mean number of respiratory‐related outpatient visits was significantly lower for treated versus untreated patients, and mean costs for these visits were $17.89 versus $35.27 over 14 days (P < 0.001) and $28.92 versus $48.77 over 28 days (P < 0.001) for treated versus untreated patients, respectively. Conclusion Our findings demonstrate that prompt antiviral treatment after influenza diagnosis may reduce HRU and costs in patients with RA.
No takes yet. Share an insight, caveat, or question.
Neuberger et al. (2022) conducted a cohort in Rheumatoid arthritis and influenza (n=3,957). Antiviral influenza treatment vs. No antiviral therapy was evaluated on Mean number of all-cause outpatient visits over 14 days (p=<0.001). Prompt antiviral treatment for influenza in patients with rheumatoid arthritis significantly reduced the mean number of all-cause outpatient visits over 14 days (0.96 vs 1.21; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: